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SUMMARY
 
The autoimmune thyroid diseases (AITDs) including Graves’ disease (GD) and autoimmune hypothy-
roidism (AIH) are the commonest of the autoimmune conditions affecting 2–5% of the western pop-
ulation. Twin studies have clearly demonstrated that AITDs are caused by a combination of both
environmental and genetic factors. Association of the HLA class II region with AITD has been docu-
mented for over 20 years now, but the primary aetiological variant in this region remains unknown.
More recently the CTLA-4 gene region has been identified as the second locus conferring susceptibility
to AITD. In contrast to HLA, a polymorphism of the CTLA-4 gene, which encodes an important neg-
ative regulator of the immune system, has been identified as a candidate for a primary determinant for
AITD. A large number of candidate gene and genome wide linkage studies have been involved in the
search for the elusive ‘third’ locus. The thyroglobulin (Tg) gene in humans maps to chromosome 8q,
which has been linked in family studies to AITD. A number of association studies in humans and the
mouse model for AITD are beginning to implicate the Tg gene although convincing evidence for a pri-
mary causative role is still needed. The establishment of large DNA disease resources along with more
detailed genetic maps and the development of faster, more effective, high throughput genotyping and
sequencing methods, provides some sense of optimism that novel loci will be identified in the near
future and the complex aetiology of AITD will be further unraveled.
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INTRODUCTION
 
The autoimmune thyroid diseases (AITDs) including Graves’ dis-
ease (GD) and autoimmune hypothyroidism (AIH) are the com-
monest of the autoimmune conditions affecting 2–5% of the
western population [1,2]. Patients with GD present with clinical
manifestations of an overactive thyroid gland (Table 1), a diffuse
swelling of the gland and in the majority of cases thyroid eye dis-
ease. A high proportion of patients present with increased serum
titres of thyroid autoantibodies including antibodies directed
against the thyrotropin (thyroid-stimulating hormone) receptor
(TSHR) which is thought to be the primary autoantigen. In con-
trast patients with autoimmune hypothyroidism (AIH) present
with the clinical manisfestations of an underactive thyroid gland
(Table 1), diffuse swelling of the gland and significant titres of
thyroid peroxidase and/or thyroglobulin autoantibodies. In
addition to the increased morbidity associated with hypo and
hyperthyroidism, which requires specialist expertise, AITD itself
is associated with an increased mortality including that from car-
diovascular diseases.
The reasons why patients with autoimmune thyroid disease
fail to maintain immune tolerance to thyroid protein(s) is
unknown although both environmental and genetic factors play
an important role in the development of disease. The fact that
AITD clusters in individuals with other autoimmune diseases,
including for example type 1 diabetes (T1D), rheumatoid arthritis
and multiple sclerosis [3], supports the hypothesis that the com-
mon autoimmune diseases share at least some aetiological
mechanisms.
It is well known that the principle effectors of the immune sys-
tem are B and T lymphocytes and that lymphocytes can be divided
into T-helper (Th) cells, which express CD4
 
+
 
 surface antigens, and
T-cytotoxic (Tc) cells, which express CD8
 
+
 
 surface antigens. The
CD4
 
+
 
 Th precursor cells are further subdivided into two popula-
tions, Th1 and Th2 cells. Th1 cells secrete interleukin-2 (IL-2),
interferon-
 
g
 
 (IFN-
 
g
 
) and tumour necrosis factor alpha (TNF-
 
a
 
),
which regulate the cellular-mediated immune response and the
induction of tissue damage [4,5]. Th2 cells secrete interleukins,
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IL-4, IL-5, IL-6 and IL-10, and are activated to provide help to B
lymphocytes for specific immunoglobulin (Ig) production [4,5].
Thyroid autoimmunity has been shown to occur via a two stage
process [6]. Stage one involves the increased appearance of
intrathyroid antigen presenting cells (APC) [7] that carry and
present thyroid autoantigens to Th cells. Stage two involves lym-
phocytes interacting with the presented autoantigens, leading to
the generation of a large number of autoreactive CD4
 
+
 
 Th lym-
phocytes, CD8
 
+
 
 Tc lymphocytes and antibody-producing B lym-
phocytes that infiltrate the thyroid parenchyma. This turns the
thyroid gland into a ‘battlefield’ where the outcome of the inter-
action between the thyrocytes and infiltrating lymphocytes deter-
mines the different clinical outcomes of AITD, believed to be due
to differences in the cytokines profile in the thyroid gland upon
infiltration (Fig. 1). In AIH there appears to be a prevalence of
Th1 cytokines, leading to a predominance of T lymphocyte immu-
nity, causing increased immune destruction of the thyroid cells
and hypothyroidism. In GD, on the other hand, there appears to
be a predominance of Th2 type inflammatory cytokines [4,8–10]
and B lymphocyte immunity producing high levels of IgG anti-
bodies specific for the TSHR which can activate the receptor,
causing thyroid cell hyperplasia and hyperthyroidism. The fact
however, that both diseases can develop in the same individual at
different time points suggest that immunological categorizations
may be overly simplistic and that cytokine patterns are dynamic
processes. This review will focus on the genetic contribution to
AITD which to a large extent involves the role of immune
response genes.
 
THE GENETIC BACKGROUND TO AITD
 
Strong evidence for a genetic basis to AITD comes from family
studies demonstrating that a family history of GD has been
reported in approximately 50% of patients [11]. Early twin stud-
ies estimated the concordance rates for disease in identical
(monozygotic) MZ twins to be 50–70% and 3–25% for noniden-
tical (dizygotic) DZ twins for GD [12]. More recent studies show
concordance rates in GD of 35% for MZ twins and 3–9% for DZ
twins [13] and rates of 55% for MZ twins and 
 
<
 
1% DZ twins for
AIH [14]. As concordance rates for disease fall well below 100%
in MZ twins, that share identical DNA, environmental (nonge-
netic) factors must also play a role in the development of AITD.
The different environmental factors that have been proposed
include bacterial [15] or viral infection [16], stressful life events
[17], synthetic chemicals [18] and iodine uptake [19] but, to date,
conclusive evidence for any is lacking and associations still remain
largely controversial.
Pioneering work in T1D suggests that most autoimmune dis-
eases are polygenic in nature implying that no single gene is either
sufficient or necessary to cause disease and that a combination of
common disease genes encode susceptibility [20]. Although envi-
ronmental agents are undoubtedly important for the develop-
ment of AITD in susceptible individuals, statistical modelling
suggests that around 79% of the predisposition to GD is due to
genetic factors [13].
Two main approaches have been employed to locate suscep-
tibility loci for AITD, namely case control candidate gene studies
and genome-wide linkage screens [21]. Case control candidate
gene studies have been employed to investigate numerous genes
for association with AITD, but to date, only the human leucocyte
region (HLA) on chromosome 6p21 and the cytotoxic T lympho-
cyte associated 4 (CTLA-4) gene on chromosome 2q33 have been
consistently shown to be associated with disease. Estimates sug-
gest that these two gene regions may account for around 50% of
the genetic contribution to GD in the UK population [22,23] and
will therefore be discussed in more detail.
 
HUMAN LEUCOCYTE REGION ASSOCIATION 
WITH AITD
 
The HLA region can be split into three different parts, class I,
class II and class III (Fig. 2a). The class I region (Fig. 2a), encodes
HLA-A, -B and -C molecules, expressed on the cell surface of
nucleated cells and are involved in the presentation of endoge-
nous antigens to CD8
 
+
 
 Tc cells. The class II region (Fig. 2b)
encodes many membrane bound proteins expressed on the cell
surface of B-lymphocytes, macrophages, dendritic cells and
activated T lymphocytes, that are involved in the processing and
presentation of exogenous antigens to CD4
 
+
 
 Th cells. At the telo-
meric end of the class II region are the DR and DQ genes which
code the 
 
a
 
 and 
 
b
 
 peptide chains of the HLA class II molecules.
The genes that encode protein involved in processing antigens for
presentation lie centrally within the class II region and include the
 
Table 1.
 
Clinical features of Graves’ disease and autoimmune 
hypothyroidism
Clinical features of GD Clinical features of AIH
Hyperthyroidism Hypothyroidism
Diffuse goitre Diffuse goitre
Tachycardia Bradycardia
Proximal myopathy Pericardial effusion
Bowel frequency Ascites
Heat intolerance, sweaty hands Gruff voice, dry skin, coarse features
Tremor Hypothermia
Thyroid eye disease
 
Fig. 1.
 
Simplified version of how Th1 and Th2 responses lead to the dif-
ferent clinical presentations of AITD.
Cellular immunity
T lymphocytes
T helper (Th) T cytotoxic cells (Tc)
Th1 pathway
Secretes IL-2, IFN-g, TNF-a, 
promoting apoptosis
Cellular immunity predominates
Destruction of thyroid gland
Th2 pathway
IL-4, IL-5, IL-6, IL-10 help activate B
lymphocytes
Production of IgG antibodies, that 
act like thyroid stimulating hormone
Stimulation of thyroid gland
Hypothyroidism Hyperthyroidism
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large multifunctional proteasomes (LMP 2 and LMP 7), trans-
porter associated with antigen processing genes (TAP1 and
TAP2) and the DM genes involved in loading of antigenic pep-
tides onto class II molecules. The DP genes, DPA1 and DPB1,
code for the 
 
a
 
 and 
 
b
 
 peptide chains that constitute the class II
molecule and like DR and DQ are also involved in antigen pre-
sentation to CD4
 
+
 
 Th cells. Finally, the class III region (Fig. 2c) is
located between the class I and class II regions and contains,
amongst others, genes encoding components of the complement
region (C2, C4 and Bf), the heat shock protein (HSP70) and
tumour necrosis factor (TNF).
 
HLA ASSOCIATION WITH GD
 
Initial association studies in GD focused on the Class I region,
with association of the HLA-A8 region [24] and in particular the
HLA-B8 region [25,26] with disease. Further studies demon-
strated strong linkage disequilibrium (LD) between HLA-B8 and
HLA-DR3 [27] suggesting that the association of HLA-B8 may
be secondary to DR3 and that the HLA-DR region played a
greater role [28]. Such assumptions were based on the finding of
greater degrees of association between disease and DR3 com-
pared with HLA-B8. Whilst such assumptions may be correct a
comprehensive statistical analysis has not been performed and
class I genes can not therefore be completely excluded from hav-
ing an independent effect. However, the majority of future studies
have focused on the HLA class II region.
As has been mentioned earlier, products of the class II gene
region aid in antigen presentation to CD4
 
+
 
 Th cells. The 
 
DRB1
 
,
 
DQA1
 
 and 
 
DQB1
 
 genes are highly polymorphic and these mol-
ecules play a major role in maintaining tolerance to self-thyroid
antigens. With aberrant expression being seen on follicular cells
(the target cells for GD) and on activated lymphocytes, the class
II genes and molecules are attractive primary candidates for
involvement with AITD.
Farid 
 
et al
 
. in 1979 [28] were the first group to use a case control
based method to show a strong association with HLA-DR3 in
Canadian Caucasians, with several other studies replicating this
result [29–31]. Despite the strong association of DR3 with disease
in Caucasians it has been observed that DR3 frequency is reduced
in Sardinian GD patients [31] and disease association in the Jap-
anese population seemed to be due exclusively to class I molecules
[32]. These and other studies suggest that either different HLA
associations are contributing to disease in different populations or
that those loci showing positive association are in LD with an as
yet unknown primary disease determinant in the HLA region.
A number of studies have subsequently replicated association
between GD and DR3 in both case control and family based
datasets and gone on to demonstrate association between the
DRB1*03-DQB1*02-DQA1*0501 extended haplotype and GD
conferring relative risks (RR) for the development of disease of
between 1·9 and 3·8 [2]. Attempts have been made to statistically
‘split’ the haplotype to determine whether individual class II
genes are conferring susceptibility to disease or whether this
really is a haplotype (
 
trans
 
-) effect. Yanagawa 
 
et al
 
. [33] have
reported a significant increase in DQA1*0501 in USA Caucasian
subjects with GD and a trend towards association of DR3 with
GD, and proposed that the DQA1*0501 association was indepen-
 
Fig. 2.
 
(a) HLA class I gene region. (b) HLA class II gene region with known haplotypes associated with GD and HT (transport associated
with antigen processing genes (
 
TAP1
 
 and 
 
TAP2
 
) and large multifunctional protein (
 
LMP
 
)). (c) HLA class II gene regions (Heat shock
protein (
 
HSP
 
), tumour necrosis factor (
 
TNF
 
)).
Class I (2000–4000 kb)(a)
(b)
(c)
Class II (1–1000 kb)
Class III (1000–2000 kb)
B C E A H G F
GD & HT 
HT
HLA-DR3 (DQB1 *02
HLA-DR4 (DQB1 *0302 DQA1 *0301
DQA1 *0501 DRB1 *03)
DRB1 *04)
B2
CYP21
A2 B1 A1 DNA DMA DMB
TAP1 TAP2
LMP2 LMP7 DOB B2 B2B3 B3 B9 AA2 B1 B1A1
DQ DRDP
C4B C4ACYP21P Bf C2 HSP70 G7 a/b TNF-a TNF-b
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dent of DR3 with DQA1*0501 conferring a greater risk [33]. Con-
firmation of stronger independent association of DQA1*0501
with GD was shown by the result still being present in DR3 neg-
ative (DR3-ve) subjects [34]. However, this study did not correct
for the number of alleles seen, which when performed leads to a
nonsignificant finding. Other authors have reported association of
DQA1*0501 with GD and others have attempted to determine if
association of the DQA1*0501 with GD is the result of LD with
DR3 [35,36], or whether 
 
DQA
 
 posed a greater, independent risk
[37,38] (see Table 2, Fig. 2b). Inconsistencies reported in such
studies are probably the result of small sample groups and com-
parisons between differing geographical and ethnic backgrounds.
Heward 
 
et al
 
. 1998 [39] performed the largest case control
investigation of association of the class II region with GD in a UK
population to date, and provided confirmation in an independent
family dataset. Strong association of both DRB1*03 (RR 
 
=
 
 2·45)
and DQA1*0501 (RR 
 
=
 
 2·26) was found but no independent
effect of DQA1*0501 was seen. Due to linkage between
DRB1*03, DQB1*02 and DQA1*0501, distribution of the haplo-
type DRB1*03-DQB1*02-DQA1*0501 between GD and control
subjects was analysed, showing association with GD (RR 
 
=
 
 2·52)
which was confirmed in the family dataset [39].
In summary, therefore, there are consistent associations
between the HLA class II genes and GD although at the present
time it remains unclear whether the primary susceptibility is the
result of a haplotype or single locus effect. Large sample sizes
with accurate class II subtyping subject to a logistic regression
analysis may be one way in which this could be resolved. Ulti-
mately, it would be important to know whether polymorphisms
leading to specific amino acid changes within peptide binding
pockets of HLA class II molecules are determining the nature of
antigen presentation and in turn the T cell repertoire conferring
susceptibility to GD.
 
HLA ASSOCIATIONS WITH AIH
 
A similar approach to detecting association of AIH with the HLA
region was adopted with initial studies focusing on the class I
region [40] and then subsequently the class II region.
Associations that have been proposed for AIH have been less
consistent than those with GD and HLA-DR3-HLA-DQw2,
HLA-DR5, HLA-DR4, HLA-DQA1*0402 (Table 2 and Fig. 2b)
have all been reported to be associated. The reasons for the lack
of consistent associations with AIH could be due to the fact that
large datasets have not been collected because patients are being
treated by their local doctors and not attending specific clinics
where recruitment of patients is easier. It seems likely however,
that AIH is also associated with DR3 [36,41].
 
Table 2.
 
Case control association studies of the HLA gene region with GD and HT
Author/year Reference
Size of data
set (n) Population
AITD 
disease HLA association
Relative  
risk (RR)
Yanagawa 
 
et al
 
. 1993 [33] 169 Caucasian (USA) GD HLA-DR3
DQA1*0501
2·46
3·71
Barlow 
 
et al
 
. 1996 [34] 187 Caucasian (UK) GD HLA-DR3
DQA1*0501
2·7
3·8
Magklabruks 
 
et al
 
. 1991 [85] 130 Caucasian (USA) GD HLA-DR3
DQB1*0201/3†
3·38
7·39†
Badenhoop 
 
et al
 
. 1992 [86] 346 Caucasian (UK & German) GD HLA-DR3 2·26
Badenhoop 
 
et al
 
. 1995 [87] 542 Caucasians (German
& Canadian)
GD DQA1*0501 2·5
Cuddihy 
 
et al
 
. 1996 [35] 218 Caucasian (USA) GD HLA-DR3
DQA1*0501†
3·5
1·8†
Heward 
 
et al
 
. 1998 [39] 592 Caucasian (UK) GD DRB1*0304-DQB1*02-DQA1*0501 2·72
Yanagawa 
 
et al
 
. 1994 [38] 237 Caucasian (USA) GD HLA-DR3
DQA1*0501
2·4
3·25
Maciel 
 
et al
 
. 2001 [37] 241 Brazilian GD DRB1*0301
DQA1*0501
2·8
3·74
Philippou 
 
et al
 
. 2001 [88] 221 Greek GD DRB1*0301-DQA1*0501 8·4 (M)
27 (F)
Bech 
 
et al
 
. 1977 [27] 2053 Caucasian (Danish) GD HLA-B8† 2·8†
243 HLA-Dw3 3·9
Moens 
 
et al
 
. 1978 [40] 262 Caucasians (Canadian) HT HLA-DRw3 3·49
Weissel 
 
et al
 
. 1980 [89] 197 Caucasian (Austrian) HT HLA-DR5 3·16
Tandon 
 
et al
 
. 1991 [41] 186 Caucasian (UK) HT HLA-DR3-HLA-DQw2 2·23
Jenkins 
 
et al
 
. 1992 [90] 143 Caucasian (UK) HT DQA1*0402
DRB1
DQB1
2·7
N/S
N/S
Wan 
 
et al
 
. 1995 [91] 388 Japanese HT DRB4*0101
HLA-A2
4·48
2·03
Petrone 
 
et al
 
. 2001 [92] 427 Caucasian (Italian) HT HLA-DRB1*04-DQB1-0301 4
Hunt 
 
et al
 
. 2001 [36] 344 Caucasian (UK) HT DRB1*03 4·0
†Result due to LD with HLA-DR3.
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CTLA-4 ASSOCIATION WITH AITD
 
The T cell receptor (TCR) dictates T cell specificity and plays a
central role in initiating activation of the immune response. Inter-
action with a presented antigen is not sufficient alone to activate
a naïve T cell and a second costimulatory signal is required,
therefore making T cell activation a two step process [42]. Step
one involves generation of an initial signal (signal 1) through
interaction of the antigenic peptide with the TCR-CD3 complex.
Step 2 involves a subsequent antigen-nonspecific costimulatory
signal (signal 2) provided primarily by the interaction of the
CD28 molecule on T cells with B7 molecules (CD80 or CD86)
expressed on activated macrophages. Signalling through CD28
expressed on activated and resting T cells provides a positive
costimulatory signal to T cells. As a method of controlling up-reg-
ulation, the CTLA-4 molecule, a homolog of CD28, expressed on
activated T cells also interacts with B7 molecules to provide an
inhibitory signal, leading to the down-regulation of T cell activa-
tion (Fig. 3). Engagement of the TCR-CD3 complex with pre-
sented antigen causes induction of CTLA-4, with CTLA-4 being
readily detected within 24 h of stimulation, with maximal expres-
sion within 2/3 days [43]. Levels of CTLA-4 expression are
increased by a CD28-generated costimulatory feedback that
effectively provides braking in proportion to acceleration from
CD28 (reviewed in [44]). As CTLA-4-CD28 molecules control
the rate of T cell activation and to a large extent the fate of the
immune response they are ideal candidates for a role in the
development of AITD.
 
CD28, CTLA-4 AND AITD
 
The genes encoding CD28 and CTLA-4 have been mapped to
human chromosome 2q33 and until recently there were only four
known polymorphisms of 
 
CTLA-4
 
 including [1] a dinucleotide
repeat microsatellite polymorphism 
 
CTLA4
 
(AT)n in the 3
 
¢
 
untranslated region of exon 4 [2], an A to G single nucleotide
polymorphism (SNP) (
 
CTLA4
 
(49)A/G) in exon 1 encoding a
threonine to alanine substitution at codon 17 and [3] a C to T
SNP (
 
CTLA4
 
[
 
-
 
318]C/T) in the promoter relative to the exon 1
start site (Table 3). The fourth, a C to T SNP in intron 1 of
 
CTLA4
 
 (
 
CTLA4
 
(1822)C/T), has been identified and been
reported to be associated with GD [45]. Yanagawa 
 
et al
 
. in 1995
[46] were the first group to report an association of polymor-
phism of 
 
CTLA-4
 
 with GD. A 106 bp allele of the 
 
CTLA4
 
(AT)n
microsatellite was found to be increased in subjects with GD
compared with control subjects. Investigation of the
 
CTLA4
 
(49)A/G polymorphism subsequently showed association
of the G allele, and the 106 bp allele of the 
 
CTLA4
 
(AT)n micro-
satellite [47] with GD and T1D with the 106 bp and G alleles
demonstrating LD. Since the initial report of association with
GD in 1995 a large number of subsequent studies have reported
association of 
 
CTLA-4
 
 polymorphism with a variety of autoim-
mune diseases in many different populations (Table 3). Replica-
tion within two UK family datasets confirmed linkage and
association of the G allele at 
 
CTLA4
 
(49)A/G and the 106 bp
allele at 
 
CTLA4
 
(AT)n with GD [22,48]. Estimates by Vaidya
 
et al
 
. [22] suggest that in the UK the 
 
CTLA4
 
 locus (
 
l
 
s 
 
=
 
 2·2) con-
fers 29–34% of the total genetic susceptibility to GD, greater
than the estimated 17–20% conferred by the MHC (
 
l
 
s 
 
=
 
 1·6).
Further 
 
in vitro
 
 studies have supported a functional role for
polymorphism of 
 
CTLA-4
 
 [49,50].
Associations of a polymorphism within a gene reported in
case control and family based studies do not imply a primary asso-
ciation with disease. The only conclusions that can be drawn are
that the polymorphism is associated with disease and that this
association may be the result of LD with another polymorphism
either within the gene of interest or a neighbouring gene. Func-
tional differences between genotypes are supportive but merely
demonstrate a difference between genotypes which may or may
not be contributing to disease. Regarding polymorphism of
 
CTLA-4
 
 it is just as likely that the association with disease is sec-
ondary to a primary locus in either CD28 or ICOS which are in
close vicinity of 
 
CTLA-4
 
 on chromosome 2q33 only 123kb and
58kb, respectively, from 
 
CTLA-4
 
. Recently however, in a major
effort to identify the primary aetiological variant in this region,
Ueda 
 
et al
 
. [51] re-sequenced the 300 kb 
 
CD28-CTLA4-ICOS
 
region, detecting 108 SNPs. The SNPs were then scored in 384 GD
cases and 652 control subjects and the extent of LD across the
 
CD28-CTLA4-ICOS
 
 region was determined  (Fig. 4). 
 
CTLA4
 
and the 5
 
¢
 
 region of 
 
ICOS
 
 were contained within a 100-kb block of
strong intermarker LD, flanked by two regions of low LD
(between 
 
CD28
 
 and 
 
CTLA4
 
) and this block was considered to
contain the causal variant. Within this block were three main
peaks of association, the first peak was 20–35kb 5
 
¢
 
 of the 
 
CTLA4
 
ATG codon, the second was 0·2–6·3kb 3
 
¢
 
 of the previously
reported end of the 
 
CTLA4
 
 transcript and the third was 49–50kb
3
 
¢
 
 of the 
 
CTLA4
 
 transcript end and 8–13 kb 5
 
¢
 
 of the 
 
ICOS
 
 ATG
codon [51]. Regression analysis eliminated the third peak as con-
taining the aetiological variant and the first peak was subse-
quently eliminated when an extended data set was scored leaving
the second peak as the most associated. The second peak con-
tained SNPs CT60, JO31, JO30 and JO27–1, with CT60 being the
most associated with GD and Hashimoto’s thyroiditis (HT) pro-
ducing RRs of 1·51 and 1·45, respectively [51]. Further support
was gained from family studies but regression analysis failed to
distinguish which SNP out of CT60, JO31, JO30 or JO27–1 was
 
Fig. 3.
 
The stimulatory pathway of CD28 and the antagonist effect of
CTLA-4 on Th cell activation. T cell activation occurs via a two stage
process. Stage 1 involves generation of a signal via the interaction of a
presented antigen with the TCR-CD3 complex. Stage 2 of T cell activation
involves a costimulatory signal from CD28 interaction with B7. Regulation
of this second stage of T cell activation is provided by a down regulation
of T cell activation by CTLA-4. Due to the negative control function of
CTLA-4, functional mutations in this gene could increase susceptibility to
autoimmune thyroid disease.
TCR-CD3 Complex
MHC Class II Molecule
Activated T cell
Antigen Presenting Cell
CD28 CTLA-4
B7 B7
ANTIGEN
–VE
TCR
+VE
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Table 3.
 
 Case control association studies of the four originally investigated CTLA-4 SNPs within GD and HT datasets of differing ethnic origin
Author/year Reference Size of data set (n) Population AITD disease Relative risk (RR)
CTLA-4(AT)n
Yanagawa et al. 1995 [46] 218 Caucasians (USA) GD 2·8
Kotsa et al. 1997 [93] 203 Caucasian (UK) GD 2·1
135 Caucasian (UK) HT 2·2
Petrone et al. 2001 [92] 427 Caucasian (Italian) HT N/S
CTLA-4(49)A/G
Nistico et al. 1996 [47] 171 Hong Kong Chinese GD 1·7
Donner et al. 1997 [94] 630 Caucasian (German & Canadian) GD 1·6
Donner et al. 1997 [95] 539 Caucasian (German & Canadian) HT 1·6
Djilali-Saiah et al. 1998 [96] 173 Caucasian (French) GD N/S
Heward et al. 1999 [48] 743 Caucasian (UK) GD 1·58
Vaidya et al. 1999 [22] 286 Caucasian (UK) GD 1·8
Buzzetti et al. 1999 [97] 336 Caucasian (Italian) GD 1·8
Villanueva et al. 2000 [98] 258 Caucasians (USA) GD 1·6
Allahabadia et al. 2001 [99] 908 Caucasian (UK) GD 1·8
Petrone et al. 2001 [92] 427 Caucasian (Italian) HT N/S
Nithiyananthan et al. 2002 [100] 532 Caucasian (UK) HT 1·57
Vaidya et al. 2003 650 Caucasian (UK) GD 1·65
CTLA-4(-318)C/T
Heward et al. 1998 [101] 546 Caucasian (UK) GD N/S
180 Hong Kong Chinese GD N/S
Braun et al. 1998 [102] 447 Caucasian (UK) HT N/S
298 Caucasian (German & Canadian) GD 2·22
237 Caucasian (German & Canadian) HT N/S
CTLA-4 (1822) C/T
Vaidya et al. 2003 [103] 650 Caucasian (UK) GD 1·64
Fig. 4. Association of SNPs within the CD28-CTLA4-ICOS gene region with GD. When association with GD was plotted for all the SNPs,
a region consisting of CTLA-4 and 5¢ ICOS gene (CTLA4 LD BLOCK) was believed to contain the aetiological variant. This diagram
highlights the CT60—JO30-JO31-J027–1 peak of linkage that is believed to contain the aetiological variant associated with GD and HT
(reprinted by permission from Nature 2003; 423:506–511. Copyright 2003, Macmillan Publishers Ltd.)
ICOSCTLA4CD28
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the aetiological variant. Although susceptibility to GD and AIH
has been mapped to a noncoding 6·1kb 3¢ region of CTLA-4, it is
important to note that other causal variants outside this region,
including smaller effects and those 5¢ of CTLA-4 have not been
completely excluded.
Further functional analysis examined steady state mRNA lev-
els of two isoforms of CTLA-4: a full length isoform (flCTLA-4)
encoded by exons 1–4 and a soluble form (sCTLA-4) that lacks
exon 3 (transmembrane domain) [51]. The ratio of sCTLA-4 to
flCTLA-4 mRNA splice forms in unstimulated CD4 T cells was
50% lower in CT60 G/G positive disease-susceptible individuals
compared with the A/A protected individuals (P = 0·002),
suggesting that the 6·1kb region determines the efficiency of splic-
ing and production of sCTLA-4, with the CT60G disease-suscep-
tibility haplotype producing less sCTLA-4 transcript than the
CT60A haplotype [51]. Whilst additional minor genetic effects
can not be completely excluded it seems likely from this study
that susceptibility to AITD conferred by the CD28/CTLA-4/
ICOS locus is the result of polymorphism within CTLA-4 itself.
The most associated GD SNPs were also found to be associated
with T1D and AIH supporting the hypothesis that CTLA-4 is
acting as a susceptibility locus for autoimmune disease in
general.
There are several potential mechanisms whereby polymor-
phism of CTLA-4 may have an effect on the counter regulation of
the CD28 costimulatory signal and confer susceptibility to AITD
and autoimmune disease in general. The competition between
CTLA-4, and CD28 for each of the CD80 and CD86 receptors
may be influenced by CTLA-4 genotype. Furthermore, soluble
CTLA-4 is present in human serum [52–54], can bind to CD80/
CD86 and may inhibit T cell proliferation via increased activation
of CD28 [54]. CTLA-4 is also constitutively expressed by T reg-
ulatory cells (T reg) [55–57], deletion of which has been shown in
animal models to lead to autoimmune disease [58–60]. Some of
the T reg function is mediated by CTLA-4 binding to the CD80/
CD86 receptors [57,61,62] such that T effector activity could be
determined by CTLA-4 genotype. Whilst these hypotheses are by
no means exhaustive nor mutually exclusive, the fine mapping of
CTLA-4 susceptibility locus has opened up a large area for future
studies which will increase our understanding of the autoimmune
disease process.
BEYOND HLA AND CTLA-4
The HLA and CTLA-4 regions may contribute to around 50% of
the susceptibility to AITD. The identification of further suscepti-
bility loci, as for most complex diseases, has involved a large num-
ber of both candidate gene and genome wide linkage studies.
Whilst attractive candidate genes have been the focus of intense
investigation and a number of chromosomal regions have been
linked to disease, the identification of a third locus for AITD is
eagerly awaited.
Candidate gene studies have focused on disease specific loci
and numerous immune response genes including TSHR, Interleu-
kin-1, Interleukin-1 Receptor Antagonist, Large Multifunctional
Protein 2 and 7 and autoimmune regulator 1 gene [63–70]. Many
of these studies have produced confusing and conflicting results
with no clear evidence of consistent replication. The explanation
for such a diversity of results is almost certainly small sample size
and also the first time effect phenomenon [71], where the first
time an effect is detected it is much greater than in subsequent
studies. This leaves the role of other genes in AITD in
controversy, with only HLA and CTLA-4 showing consistent
association.
Genome wide screens have, to date, proved no more success-
ful than candidate gene studies in terms of delivering a novel
locus. The first genome wide screen in GD in 56 multiplex families
reported three areas of linkage designated GD-1 on chromosome
14q31, GD-2 on chromosome 20q11.2 and GD-3 on chromosome
Xq21. Subsequently two further regions of linkage have been
reported to AIH, HT1 on chromosome 13q33, HT2 on chromo-
some 12q22, and one area of linkage to AITD in general, AITD-
1 on 6p close to, but distinct to HLA [72]. Upon increasing the
number of families to 102 and repeating the genome screen, some
support was gained for GD-1, GD-2 and HT-2, with GD-3 and
HT-1 no longer appearing associated and the exact position of
AITD-1 on 6p being questioned [73]. Independent attempts to
replicate these findings have been largely unsuccessful [74,75].
Sakai et al. [76] have reported linkage to AITD on chromosome
5q31–33 in a Japanese sib-pair family dataset. This region is of
particular interest as it contains a large cytokine gene cluster
including IL-3, IL-9, IL-13 and in particular IL-4 and IL-5 that
may play a role in Th2 responses that lead to AIH, with replica-
tion being eagerly awaited.
Genome-wide linkage analysis of Japanese sib-pairs recently
demonstrated suggestive evidence for linkage between chromo-
some 8q23-q24 and HT [76]. Linkage analysis of a further data
set of families with AITD replicated this original finding with
evidence of allelic association between subjects with AITD and
two chromosomal markers on chromosome 8q23-q24 namely
Tgms2, located within the thyroglobulin (Tg) gene and D8S284,
in the Tg region [77]. As human Tg is a major autoantigen for
thyroid disease and is present in almost all patients with AITD
[78–80], Tg on chromosome 8q23-24 is a good candidate gene
for AITD. We have performed a case control association study
on patients with AITD and controls in the UK [81]. No differ-
ences in allele frequencies were observed between AITD cases
and controls for D8S284. Compared with the 3 common alleles
(frequencies > 10%) the rare alleles of Tgms2 were, however,
increased, P = 0·001 at Tgms2. This group included the 336 bp
allele (increased in cases versus controls, P < 0·001) which has
previously been reported to be associated with AITD. Whilst
these findings may represent a random chance event, taken
together with previous reports of linkage and association, this
may be an example of a rare causal variant of a complex disease.
Subsequent to this, resequencing of Tg has identified 14 novel
SNPs, 3 of which in exons 10, 12 and 33 have been reported to
be associated with AITD [82]. Resequencing of the same exons
of the mouse Tg revealed a unique SNP haplotype present in
50% of mouse strains susceptible to thyroiditis which was not
present in strains resistant to thyroiditis. This exciting work
clearly needs replication in an independent data set. Further-
more, the authors also concluded that polymorphism within Tg
may not be the primary aetiological variant and polymorphism
in a neighbouring gene can not be excluded as conferring sus-
ceptibility to AITD.
Whilst both the HLA and CTLA-4 regions have been
reported to be linked to GD in a UK data set, neither region has
been detected in the genome screens described above. The rea-
sons for this seem to relate to the individual contribution of each
locus to disease. Unlike T1D [20] for example, the HLA region is
not exerting a major effect in AITD as reflected in the odds ratios
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observed in association studies [2]. Whilst CTLA-4 region is
exerting a greater effect in AITD compared with T1D, its contri-
bution is still modest, and probably of the same order of magni-
tude to that seen regarding the insulin gene region in T1D which
has not been detected by linkage analysis in many large T1D fam-
ily data sets [83]. The general lack of linkage to HLA and CTLA-4
regions in genome wide linkage analyses is however, an important
observation. This clearly suggests that novel candidates have
failed to be identified because there is no single gene region exert-
ing a major effect in AITD and that other as yet unknown loci are
likely to be of a similar or smaller magnitude than HLA and
CTLA-4.
CONCLUSIONS AND FUTURE DIRECTIONS
Over the last 10 years we have only seen the identification of one
new susceptibility gene (CTLA-4) for AITD and a third locus
(Tg), awaits confirmation. However, with the publication of the
draft human genome [84], the establishment of SNP maps, the
resequencing of many immune response genes and the develop-
ment of faster, more effective, high throughput genotyping meth-
ods, there is now some sense of optimism that new loci will be
identified. The funding of large national DNA collections will also
help overcome the problems of inadequately sized data sets and
increase our chances of detecting individual genetic effects con-
tributing to AITD most of which are likely to be smaller than orig-
inally envisaged.
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